26 March 2019 | TRANSVAC: European Vaccine Research and Development Infrastructure

Open Call for Vaccine Development Services


TRANSVAC2
– EU-funded project offers high-quality technical services to support the development of prophylactic and therapeutic vaccines for both human and animal use. These services are not restricted to any disease in particular.

Except for the few cases indicated on the website, services will be offered free of charge!

Academic and non-academic research groups, SMEs and industries can apply but only to service infrastructures outside their own country.

IMPORTANT DATES
Opening of the call: 15 February 2019
Submission deadline: 15 April 2019
Evaluation and Selection deadline: 31 May 2019
Feedback to applicants: 1 June 2019

For more information about the services offered by TRANSVAC, the eligibility criteria and the application process, as well as to download the application form, please visit: http://www.transvac.org

If you have any specific questions, you can contact the project management team at: transvacinfo@euvaccine.eu

Feel free to spread information about this call among your colleagues working in or promoting research in vaccine development.

 

Services still available free of charge:

Platform Clinical Trial Support

  • Human clinical trial support – ECRIN, FR

Platform Animal Models

  • In-vivo imaging in NHPs at different levels of containment – CEA, FR
  • Immunogenicity and efficacy studies in mice – SSI, DK
  • Immunogenicity, challenge and efficacy studies in pigs, ruminants and other farm animals – SWR, NL
  • Immunogenicity and efficacy studies in mice – HZI, DE
  • Antigen tracking, immunogenicity, challenge and efficacy studies in pigs, ruminants and other farm animals – INRA, FR
  • Immunogenicity and efficacy studies in pigs, ruminants and ferrets – IRTA, SP (please check availability with provider, availability in February 2019 call will depended on project scope)

 

Platform Immunocorrelates and System Biology

  • Next-generation sequencing and data analysis – Bioaster, FR
  • Mass cytometry and multidimensional data analysis – CEA, FR
  • Metabolomics profile – LU, NL
  • Mathematical modelling –  UNISI, IT
  • Mathematical modelling – ETHZ, CH
  • Multiplex cytokine/chemokines analysis – UNISI, IT
  • Metabolomics Imaging by Mass Spectrometry, for in-situ adjuvant/antigen tracking and inflammation monitoring – Bioaster , FR

 

Platform Technology

  • Cross-platform screening and optimisation service
  • Single protein expression in Nicotiana – IME, DE
  • Mammalian and insect cells (transient and constitutive) expression platforms – iBET, PT
  • Protein expression in Pichia pastoris – BPRC, NL
  • Cross-platform expression screening (bacterial, plant, eukaryotic) – BPRC, NL; SSI, DK; IME, DE; iBET, PT
  • Expression of vaccine antigens in Adenovirus and MVA vectors – UOXF, UK
  • Construction of commensal bacterial strains displaying selected antigens – UNISI, IT
  • Adjuvants and delivery systems
  • Development and characterisation of vaccine formulations with liposomal adjuvants CAF01 and CAF09b – SSI, DK
  • Formulation and characterisation of candidate antigens paired with mucosal adjuvants – HZI, DE
  • Adjuvant and formulation services –  VFI, UK
  • Formulation of antigens in LPS adjuvants – ITV, NL

 

  • Analytical services
  • Single compound analysis (structural integrity, purity, binding) – IME, DE
  • SPR-analytics (kinetic binding parameters, CFCA) – IME, DE
  • Impurity-related assays for process development – IME, DE
  • Luminex potency assay for cytokine/chemokine responses in human blood – LSHTM, UK
  • Flow-cytometry for antigen-specific polyfunctional T-cell response – CEA, FR
  • (Semi) quantitative proteome analysis based on mass spectrometry – ITV, NL
  • Cell-based reporter assays for characterisation of innate immune receptor induced signalling cascades – BPRC, NL
  • Pre-clinical GLP production services
  • Preclinical GLP production services in yeast (Pichia pastoris) and/or plant (Nicotiana) expression platforms – IME, DE
  • Preclinical GLP production services in mammalian and/or insect cells (transient and constitutive) expression platforms – iBET, PT
  • Production of GMP compliant Adenovirus and/or MVA vector(s) expressing antigen(s) of interest – UOXF, UK